Skip Nav Destination
Issues
1 March 2009
-
Cover Image
Cover Image
BCRP was detected in WiDr HF (A) and WiDr LF cells (B) by the primary antibody BXP-21 in conjunction with a FITC-conjugated second antibody (green fluorescence). Cell nuclei were stained with propidium iodide (red staining). Cells in the control panels were treated with mouse IgG2a, instead of BXP-21, and FITC-conjugated second antibody. (C) Detailed picture of WiDr LF cells, showing in the lower and right sides optical X-Z and Y-Z sections perpendicular to the selected plane (shown in dark lines in the X-Y section image). For details, see Lemos et al., in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Marcus M. Schittenhelm; Christian Kollmannsberger; Karin Oechsle; Amy Harlow; Jason Morich; Friedemann Honecker; Raffael Kurek; Stephan Störkel; Lothar Kanz; Christopher L. Corless; Kwok-Kin Wong; Carsten Bokemeyer; Michael C. Heinrich
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
Ralph G. Zinner; Brittany L. Barrett; Elmira Popova; Paul Damien; Andrei Y. Volgin; Juri G. Gelovani; Reuben Lotan; Hai T. Tran; Claudio Pisano; Gordon B. Mills; Li Mao; Waun K. Hong; Scott M. Lippman; John H. Miller
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection
Severine Loisel-Meyer; Tania Felizardo; Jacopo Mariotti; Miriam E. Mossoba; Jason E. Foley; Robert Kammerer; Nobuo Mizue; Robert Keefe; J. Andrea McCart; Wolfgang Zimmermann; Boro Dropulic; Daniel H. Fowler; Jeffrey A. Medin
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds